Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 2c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.23 million versus the consensus estimate of $7.07 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• HA Sustainable Infrastructure Ca (HASI) PT Lowered to $45 at BofA Securities
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24